Moleculin Biotech Inc (MBRX): Next-Year EPS Estimate 42.10%
As of 2026-08-25, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 42.10%. Featured in our EPS revision report on 2026-08-12.
On 2026-08-17, analyst consensus for MBRX's next-year EPS growth shifted from 42.11% to 42.10% — a negative change of 0.01 percentage points. The revised estimate has been sustained across 8 subsequent trading sessions. Current-year growth is projected at 87.02%.
What's Driving This
The primary structural driver behind MBRX's rise is an August 14 upgrade to next-year EPS growth estimates, from 41.61% to 42.11%, with the estimate subsequently holding near
Generated 2026-08-21 from news as of 2026-08-21
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 42.10%
- EPS growth this year
- 87.02%
- EPS next quarter (est)
- -$0.65
- Last price
- $0.61
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 42.10% | 87.02% | -$0.65 | $0.61 |
| 2026-08-24 | 42.10% | 87.02% | -$0.65 | $0.61 |
| 2026-08-23 | 42.10% | 87.02% | -$0.65 | $0.59 |
| 2026-08-21 | 42.10% | 87.02% | -$0.65 | $0.59 |
| 2026-08-20 | 42.10% | 87.02% | -$0.65 | $0.59 |
| 2026-08-19 | 42.10% | 87.02% | -$0.65 | $0.57 |
| 2026-08-18 | 42.10% | 87.02% | -$0.65 | $0.61 |
| 2026-08-17 | 42.10% | 87.02% | -$0.65 | $0.61 |
| 2026-08-16 | 42.11% | 86.85% | -$0.66 | $0.61 |
| 2026-08-14 | 42.11% | 86.85% | -$0.66 | $0.61 |
| 2026-08-13 | 41.61% | 83.23% | -$1.55 | $0.57 |
| 2026-08-12 | 41.61% | 83.23% | -$1.55 | $0.52 |
| 2026-08-11 | 41.61% | 83.23% | -$1.55 | $0.44 |
| 2026-08-10 | 41.61% | 83.23% | -$1.55 | $0.43 |
| 2026-08-09 | 41.61% | 83.23% | -$1.55 | $0.41 |
| 2026-08-07 | 41.61% | 83.23% | -$1.55 | $0.41 |
| 2026-08-06 | 41.61% | 83.23% | -$1.55 | $0.38 |
| 2026-08-05 | 41.61% | 83.23% | -$1.55 | $0.39 |
| 2026-08-04 | 41.61% | 83.23% | -$1.55 | $0.41 |
| 2026-08-03 | 37.35% | 81.30% | -$1.60 | $0.43 |
| 2026-08-02 | 37.35% | 81.30% | -$1.60 | $0.40 |
| 2026-07-31 | 37.35% | 81.30% | -$1.60 | $0.40 |
| 2026-07-30 | 37.35% | 81.30% | -$1.60 | $1.02 |
| 2026-07-29 | 37.35% | 81.30% | -$1.60 | $1.36 |
| 2026-07-28 | 37.35% | 81.30% | -$1.60 | $2.19 |
| 2026-07-27 | 37.35% | 81.30% | -$1.60 | $2.19 |
| 2026-07-26 | 37.35% | 81.30% | -$1.60 | $2.12 |
| 2026-07-24 | 37.35% | 81.30% | -$1.60 | $2.12 |
| 2026-07-23 | 37.35% | 81.30% | -$1.60 | $2.08 |
| 2026-07-22 | 37.35% | 81.30% | -$1.60 | $2.10 |
Reports Featuring MBRX
Recent News
- Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialGlobeNewswire
- MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of SignificanceStocktwits
- Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Moleculin Biotech Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 42.10%, based on analyst consensus.
When was the latest EPS estimate revision for MBRX?▾
The most recent revision occurred on 2026-08-17, when analysts adjusted the next-year EPS growth estimate from 42.11% to 42.10%.
What sector and industry does Moleculin Biotech Inc belong to?▾
Moleculin Biotech Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MBRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moleculin Biotech Inc (MBRX) appears here because it was detected by our daily top-EPS-revision-performer screen.